- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| Do | Alvotech higher on positive data backing biosimilar to Takeda's Entyvio | 4 | Seeking Alpha | ||
| Do | Alvotech - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Do | Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio | 105 | GlobeNewswire (Europe) | The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland... ► Artikel lesen | |
| Mo | Alvotech Enters Supply, Commercialization Deal With Sandoz Covering Biosimilar Candidates | 16 | RTTNews | ||
| Mo | Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates | 124 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 29.01. | Alvotech - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 29.01. | Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar | 53 | Seeking Alpha | ||
| 29.01. | Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg | 209 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 06.01. | Alvotech: Transactions of Managers and Closely Associated Persons | 17 | GlobeNewswire (USA) | ||
| 06.01. | Alvotech announces CEO transition | 10 | Seeking Alpha | ||
| 06.01. | Alvotech Appoints Lisa Graver As CEO, Rbert Wessman To Continue As Executive Chairman | 3 | RTTNews | ||
| 06.01. | Alvotech names Lisa Graver as new CEO as founder steps back | 4 | Investing.com | ||
| 06.01. | Alvotech announces planned CEO succession and leadership transition | 382 | GlobeNewswire (Europe) | R- bert Wessman to continue serving as Executive Chairman in full-time capacityLisa Graver appointed Chief Executive Officer REYKJAVIK, ICELAND (January 6, 2026) - Alvotech (NASDAQ: ALVO), a global... ► Artikel lesen | |
| 06.01. | Alvotech Secures $100 Million Term Loan Facility Led By GoldenTree | 12 | pulse2.com | ||
| 02.01. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 31.12.25 | Alvotech Secures Term Loan Facility of USD 100 Million | 6 | GlobeNewswire (USA) | ||
| 29.12.25 | Alvotech: Changes in company's own shares | 13 | GlobeNewswire (USA) | ||
| 23.12.25 | Alvotech - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Alvotech's Financial Calendar for 2026 | 17 | GlobeNewswire (USA) | ||
| 22.12.25 | Alvotech announces European launch of biosimilar to Simponi | 14 | Seeking Alpha |
1 2 3 4 5 Weiter >>
124 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 1,410 | -1,40 % | Regenerative Medizin auf dem Vormarsch: Exosomen, Gen- und Zelltherapien als Wegbereiter neuer Heilansätze | ||
| QIAGEN | 43,475 | -0,84 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,82 | +0,14 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 73,21 | 0,00 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| RECURSION PHARMACEUTICALS | 3,565 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,95 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 16,550 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,82 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| ERASCA | 11,885 | +5,74 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| LIMINATUS PHARMA | 2,030 | 0,00 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,94 | 0,00 % | Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy | ||
| SUMMIT THERAPEUTICS | 13,860 | 0,00 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ALUMIS | 26,340 | 0,00 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BIONTECH | 89,80 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| IMMUNOVANT | 24,060 | -4,33 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
ALVOTECH SDR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,91 % bei einem Aktienkurs von 4,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.